This segment encompasses a wide array of analytical and bioanalytical services crucial for drug development. Frontage's laboratories are equipped with advanced technologies for method development, validation, and sample analysis, ensuring data integrity and regulatory compliance. The services support pharmacokinetic and pharmacodynamic studies, bioavailability and bioequivalence assessments, and biomarker analysis. Research and development activities focus on enhancing analytical techniques, expanding assay capabilities, and integrating automation to improve efficiency and throughput. These services are vital for pharmaceutical and biotechnology companies seeking to understand drug behavior in biological systems and meet stringent regulatory requirements. The segment's market positioning is strengthened by its global presence and commitment to quality, enabling it to serve a diverse clientele across various therapeutic areas.

This segment provides comprehensive support for drug development, from early discovery to clinical trials. Frontage offers services including medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), toxicology, and formulation development. Research and development efforts are directed towards identifying novel drug targets, optimizing lead compounds, and conducting preclinical and clinical studies. The segment leverages advanced technologies such as high-throughput screening, in silico modeling, and bioimaging to accelerate drug discovery. It also focuses on developing innovative formulations and delivery systems to improve drug efficacy and patient compliance. By integrating these services, Frontage assists pharmaceutical and biotechnology companies in navigating the complex drug development pathway, reducing time-to-market, and improving the success rate of new therapies. The segment's competitive advantage lies in its ability to provide integrated solutions and its expertise in regulatory affairs.